Inherited Orphan Blood Diseases Patients Face Stagnant Treatment Future.

15:30 EST 14 Feb 2013 | BioPortfolio

GBI Research

Generally unimpressive treatment line-ups combined with weak product pipelines will lead to modest growth for several inherited orphan blood disease markets, states business intelligence provider GBI Research.

According to the firm’s new report*, the global therapeutic markets for sickle cell anemia, thalassemia and hereditary angioedema (HAE) are all expected to exhibit uninspired growth. The greatest value increase is expected from the sickle cell anemia market, which is forecast to climb at a Compound Annual Growth Rate (CAGR) of 9%, from US$36m in 2012 to US$70m in 2019.

Meanwhile, the global HAE therapeutics market is predicted to increase at a miserly CAGR of 3% during the same period, from US$1.5 billion to US$1.9 billion.

Kimberley Carter, Associate Analyst at GBI Research states: “Even though orphan blood disorders are rare, the three diseases featured in this report are hereditary and have a large impact on the lives of the families and ethnic groups afflicted by these diseases. Many of these diseases cause debilitating health issues and limit lifespan. Because of this there is a great need for curative and disease modifying therapies.

“While this may require significant R&D investment, any drugs that are successful in treating these diseases can be expected to be priced at the highest premium range.”

All three ailments studied in the new report have weak product pipelines, with most upcoming treatments either too similar to currently available options, or insufficiently promising to make any real impact.

At present, only the HAE market can be considered strong, thanks largely to the dominance of Cinryze – the only branded therapy taken according to a regular dosing regimen. Cinryze will continue to dominate the HAE market as long as it remains unique, and an exceptionally weak pipeline will most likely ensure this remains the case.

* Inherited Orphan Blood Disorders Therapeutics Market to 2019 - Breakthrough Drugs Remain Elusive Against Backdrop of High Unmet Need

This report provides insights into the up-and-coming trends of a portion of the inherited orphan blood disorder pharmaceutical market by examining sickle cell anemia, thalassemia and Hereditary Angioedema (HAE) in seven major markets.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

-ABOUT GBI RESEARCH-

GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.

Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GBI Research.

The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions and recommendations that GBI Research delivers will be based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such GBI Research can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect.

****
Publisher: GBI Research

Published: Jan'13

Reference code: GBIHC293MR

Report Price: $3500 (Single User License)

NEXT ARTICLE

More From BioPortfolio on "Inherited Orphan Blood Diseases Patients Face Stagnant Treatment Future."

Search BioPortfolio:
Advertisement

Relevant Topics

Blood
Latest News Clinical Trials Research Drugs Reports Corporate
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Top five promising drugs Phase II (November 2013)
Latest News Clinical Trials Research Drugs Reports Corporate
THE FIVE MOST PROMISING DRUGS ENTERING PHASE II TRIALS Drug Disease Company Sel-G1 Sickle cell anemia Selexys Pharmaceuticals NSI-566 Amyotrophic lateral sclerosis...

Advertisement

Searches Linking to this Story